Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Rituxan data in indolent NHL

Idec (IDPH) and partner Genentech (DNA) said that in a study of 188

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE